Contributo di una variante prevalente in Europa vicino a CD83 e di una variante prevalente in Asia orientale vicino a IL17RB al rischio di herpes zoster nel trattamento con tofacitinib: risultati delle meta-analisi dello studio sull'associazione a livello di genoma
Bing N,
Zhou H,
Chen X,
Hirose T,
Kochi Y,
Tsuchida Y,
Ishigaki K,
Sumitomo S,
Fujio K,
Zhang B,
Valdez H,
Vincent MS,
Martin D,
Clark JD.
Arthritis Rheumatol. 2021;73(7):1155–66
Genetic analysis of tofacitinib-treated subjects with RA or PsO identified multiple loci associated with increased herpes zoster (HZ) risk.It is well known that HZ risk is elevated in subjects with RA compared with the general population, and that treatment with JAK inhibitors may result in increased risks compared with TNFi and other bDMARD treatments. To this end, Bing, et al. used genome-wide association studies to identify genetic factors associated with an increased risk/faster onset of HZ in subjects with RA or PsO receiving tofacitinib treatment.
